Relationship between number of bacteria and their probiotic effects

Article English OPEN
Minelli, Elisa BErtazzoni ; Benini, Anna (2011)
  • Publisher: Microbial Ecology in Health and Disease
  • Journal: Microbial Ecology in Health and Disease (issn: 1651-2235, eissn: 1651-2235)
  • Related identifiers: doi: 10.3402/mehd.v20i4.7577

The effects of probiotics on human health are positive and well defined in diarrhoea treatment. There are no clinical results regarding the relationship with dose or duration of treatment. The results from clinical studies have not been conclusive in that the effects of probiotic are dependent on strains, acute or chronic gastrointestinal infection and immunological or inflammatory disease and different dose and duration of treatment. The concentration of probiotics needed to obtain a clinical effect is often quoted as ≥10? cfu/ml in the small bowel and ≥10? cfu/g in the colon. The dose for treatment of an acute illness by a particular probiotic agent may be lower or higher, in the order of 10-fold or 100-fold or more in terms of colony forming units (cfu). In acute infectious diarrhoea it seems that higher doses of probiotics given for short courses are more effective than lower doses. In chronic or immunological diseases (allergic, inflammatory and/or immune diseases) the effects depend also on the interaction with gut immune system and duration of treatment. To evaluate the efficacy of probiotics it may be essential to identify specific target groups of individuals with more specific higher susceptibilities to the potential effects of probiotics.Key words: Probiotics, acute infectious diarrhoea, immunological disease, efficacy
  • References (20)
    20 references, page 1 of 2

    1. Christensen HR, Larsen CN, Kaestel P, Rosholm LB, Sternberg C, Michaelsen KF, et al. Immunomodulating potential of supplementation with probiotics: a dose-response study in healthy young adults. FEMS Immunol Med Microbiol. 2006;/47:/380 90.

    2. Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol. 2003;/17:/725 40.

    3. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004;CD003048.

    4. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 2006;/6:/374 82.

    5. Vesa T, Pochart P, Marteau P. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment Pharmacol Ther. 2000;/14:/823 8.

    6. Donnet-Hughes A, Rochat F, Serrant P, Aeschlimann JM, Schiffrin EJ. Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose. J Dairy Sci. 1999;/82:/863 9.

    7. Sanders ME. Probiotics: considerations for human health. Nutr Rev. 2003;/61:/91 9.

    8. Oozeer R, Leplingard A, Mater DD, Mogenet A, Michelin R, Seksek I, et al. Survival of Lactobacillus casei in the human digestive tract after consumption of fermented milk. Appl Environ Microbiol. 2006;/72:/5615 7.

    9. Elmer GW, Corthier G. Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice. Can J Microbiol. 1991;/37:/315 7.

    10. Girard P, Pansart Y, Lorette I, Gillardin JM. Dose-response relationship and mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhea in rats. Dig Dis Sci. 2003;/48:/770 4.

  • Metrics
    No metrics available
Share - Bookmark